208 Users Online
Animal Models for Acute Radiation Syndrome (ARS) Market Segmented By Treatment Type such as Mouse, Rat, Guinea pig, Ferret, Rabbit, Canine (Beagle), Minipig and NHP Nonhuman primate
The clinical outcome of acute radiation syndrome particularly depends on the absorbed radiation dose and its distribution. Multiorgan failure and Multiorgan involvement need be taken into account. Radiation-induced damage to the skin, lung hematopoietic tissue, and gastrointestinal (GI) systems signifies a central role in the treatment and diagnosis of the victims affected by radiation accident.
In case of accident situations the assessment of radiation effects can analyzed. As reliable secondary information for the radioactivity exposure from physical dosimetry and results from biodosimetric methods are typically not available.
There are numerous reasons for the lack of FDA approval of medical countermeasures (MCM) for various sub-syndromes of DEARE (cardiovascular disease, lung fibrosis and multiple organ injury) and Animal Models for Acute Radiation Syndrome ARS.
One significant challenge is the lack of well-characterized reliable and authenticated large animal models appropriate to symbolize the pathophysiology of human body for studying radiation exposure. The advanced development and radiation MCM for acute radiation syndrome (ARS) requires FDA approval of practical demo that the MOA of such MCM is predictive in animal models representing response in humans.
The Animal Models for Acute Radiation Syndrome (ARS) involves an interactive and practical solution for testing radiation exposure through various approved models. The major factor propelling the growth of Animal Models for Acute Radiation Syndrome (ARS) market is heavy demand for the animal models for drug testing for the Animal Models for Acute Radiation Syndrome (ARS).
As most of the primary treatment regimen is gaining the share considering to the higher demand for injury related radiation exposure treatment supported by the Animal Models for Acute Radiation Syndrome (ARS) delivering the value of radiation exposure study.
Additionally, restriction of FDA on human testing in acute radiation syndrome is anticipated to boost the market growth for the Animal Models for Acute Radiation Syndrome (ARS), owning to increasing study potential in large study model. Mimicking the effects on the human body.
However, restriction in opting for larger animal study models and compulsory affiliation to government bodies for utilizing Animal Models for Acute Radiation Syndrome (ARS) is anticipated to restrain the growth of the Animal Models for Acute Radiation Syndrome (ARS) market.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
|
Treatment Type |
|
|
End User |
|
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionGeographically, global Animal Models for Acute Radiation Syndrome (ARS) market is segmented into seven key regions viz. North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. North America dominates the overall Animal Models for Acute Radiation Syndrome (ARS) Market.
Constant requirement for the associated study potential of the radiation exposure caused by the acute radiation syndrome (ARS), important regulatory approvals concerning the study based on the animal models, and strict guidelines from government body and drug associations.
Is fueling the growth Animal Models for Acute Radiation Syndrome (ARS) market in North America. Additionally in East Asia region considerably higher market growth rate is expected due to availability of different animal models that are helping the research organization involving in the facilitation for utilizing Animal Models for Acute Radiation Syndrome (ARS) treatment.
Some of the major key players competing in the global Animal Models for Acute Radiation Syndrome (ARS) Market are Covance Inc, Taconic Biosciences, Inc, Charles River, Jackson Laboratories, Bloomington Drosophila Stock Center, JANVIER LABS, Vienna Drosophila RNAi Center, Sinclair Research, Horizon Discovery Group plc among others.
Sales Team
Client Partner
